The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 402,191 share decrease in total short interest for Columbia Banking System Inc (COLB - Get Report), to 1,301,981, a decrease of 23.60% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for COLB at the 01/12/2018 settlement increased to 262,026, as compared to 190,757 at the 12/29/2017 report. That brought "days to cover" down to 4.97, a 44.38% decrease from the 8.93 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for COLB at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where COLB had been shorted as a hedge. The chart below shows the one year performance of COLB shares, versus its 200 day moving average. Looking at this chart, COLB's low point in its 52 week range is $35.67 per share, with $48.06 as the 52 week high point — that compares with a last trade of $42.15. COLB makes up 1.90% of the PowerShares S&P SmallCap Quality Portfolio ETF (XSHQ)
More from Stocks
PG&E Warns of Potential Major Power Shut Off on Wednesday
Wind storm could trigger a public safety power shutoff for a portion of homes and businesses in the Sierra Foothills, North Valley and North Bay.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Could Netflix Survive on Just Its Own Original Content?
Netflix says that viewers shell out for original shows like Stranger Things and Orange is the New Black -- but production costs have ballooned roughly 30% since last year, which has many investors spooked.
Jim Cramer: Mastercard Is One Thing Money Can Buy
The slogan was: There are some things money can't buy; for everything else, there's Mastercard. Fast forward more than two decades and the world of fintech and digital payment processing has changed, and Mastercard has changed right along with it.